参考文献/References:
[1]Sidney S,Quesenberry CP Jr,Jaffe MG,et al. Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals[J]. JAMA cardiol,2016,1(5): 594-599.
[2]中国心血管健康与疾病报告2019概要[J]. 中国循环杂志,2020,35(09):833-854.
[3]Ference BA,Graham I,Tokgozoglu L,et al. Impact of Lipids on Cardiovascular Health:JACC Health Promotion Series[J]. J Am Coll Cardiol,2018,72(10):1141-1156.
[4]Newman CB,Preiss D,Tobert JA,et al. Statin Safety and Associated Adverse Events:A Scientific Statement From the American Heart Association[J]. Arterioscler Thromb Vasc Biol,2019,39(2):e38-e81.
[5]Chait A,Eckel RH. Lipids,lipoproteins,and cardiovascular disease:clinical pharmacology now and in the future[j]. J Clin Endocrinol Metab,2016,101(3):804-814.
[6]Sabatine MS,Giugliano RP,Keech AC,et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med,2017,376(18):1713-1722.
[7]Schwartz GG,Steg PG,Szarek M,et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med,2018,379(22):2097-2107.
[8]Tsimikas S. RNA-targeted therapeutics for lipid disorders[J]. Curr Opin Lipidol,2018,29(6):459-466.
[9]Alexander VJ,Xia S,Hurh E,et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels[J]. Eur Heart J,2019,40(33):2785-2796.
[10]Ashwell G,Morell A. Gilbert Ashwell:sweet on science[J]. Nat Med,2008,14(6):608.
[11]Springer AD,Dowdy SF. GalNAc-siRNA conjugates:leading the way for delivery of RNAi therapeutics[J]. Nucleic Acid Ther,2018,28(3):109-118.
[12]Steer CJ,Ashwell G. Studies on a mammalian hepatic binding protein specific for asialoglycoproteins. Evidence for receptor recycling in isolated rat hepatocytes[J]. J Biol Chem,1980,255(7):3008-3013.
[13]Lee YC,Townsend RR,Hardy MR,et al. Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin.Dependence on fine structural features[J]. J Biol Chem,1983,258(1):199-202.
[14]Crooke ST,Witztum JL,Bennett CF,et al. RNA—Targeted therapeutics[J]. Cell Metab,2018,27(4):714-739.
[15]Prakash TP,Graham MJ,Yu J,et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice[J]. Nucleic Acids Res,2014,2(13):8796-8807.
[16]Schirle NT,Sheu-Gruttadauria J,MacRae IJ. Structural basis for microRNA targeting[J]. Science,2014,346(6209):608-613.
[17]Salomon WE,Jolly SM,Moore MJ,et al. Single-Molecule Imaging Reveals that Argonaute Reshapes the Binding Properties of Its Nucleic Acid Guides[J]. Cell,2015,162(1):84-95.
[18]Kwakernaak AJ,Lambert G,Dullaart RP. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins[J]. Clin Biochem,2014,47(7-8):679-682.
[19]Cohen JC,Boerwinkle E,Mosley TH Jr,et al. Sequence variations in PCSK9,low LDL,and protection against coronary heart disease[J]. N Engl J Med,2006,354(12):1264-1272.
[20]Ward NC,Page MM,Watts GF. PCSK9 inhibition 2018:riding a new wave of coronary prevention[J]. Clin Sci (Lond),2019,133(2):205-224.
[21]Fitzgerald K,White S,Borodovsky A,et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med,2017,376(1):41-51.
[22]Ray KK,Wright RS,Kallend D,et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med,2020,382(16):1507-1519.
[23]彭道泉,杨阳. 血脂管理与ASCVD的回顾与展望[J]. 临床心血管病杂志,2020,36(09):783-786.
[24]Tsimikas S. A test in context:lipoprotein(a):diagnosis,prognosis,controversies,and emerging therapies[J]. J Am Coll Cardiol,2017,69(6):692-711.
[25]Shah NP,Pajidipati NJ,McGarrah RW,et al. Lipoprotein (a):an update on a marker of residual risk and associated clinical manifestations[J]. Am J Cardiol,2020,126:94-102.
[26]Tsimikas S,Gordts P,Nora C,et al. Statin therapy increases lipoprotein(a) levels[J]. Eur Heart J,2020,41(24):2275-2284.
[27]Clarke R,Peden JF,Hopewell JC,et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease[J]. N Engl J Med,2009,361(26):2518-2528.
[28]Viney NJ,Capelleveen JC V,Geary RS,et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a):two randomised,double-blind,placebo-controlled,dose-ranging trials[J]. Lancet,2016,388(10057):2239-2253.
[29]Tsimikas S,Karwatowska-Prokopczuk E,Gouni-Berthold I,et al. Lipoprotein(a) reduction in persons with cardiovascular disease[J]. N Engl J Med,2020,382(3):244-255.
[30]Taskinen MR,Borén J. Why Is apolipoprotein CⅢ emerging as a novel therapeutic target to reduce the burden of cardiovascular disease?[J]. Curr Atheroscler Rep,2016,18(10):59.
[31]Wulff AB,Nordestgaard BG,Tybj?rg-Hansen A. APOC3 Loss-of-Function Mutations,Remnant Cholesterol,Low-Density Lipoprotein Cholesterol,and Cardiovascular Risk:Mediation- and Meta-Analyses of 137895 Individuals[J]. Arterioscler Thromb Vasc Biol,2018,38(3):660-668.
[32]TG and HDL Working Group of the Exome Sequencing Project,National Heart,Lung,and Blood Institute,Crosby J,Peloso GM,et al. Loss-of-function mutations in APOC3,triglycerides,and coronary disease[J]. N Engl J Med,2014,371(1):22-31.
[33]Kersten S. Angiopoietin-like 3 in lipoprotein metabolism[J]. Nat Rev Endocrinol,2017,13(12):731-739.
[34]Shimamura M,Matsuda M,Yasumo H,et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase[J]. Arterioscler Thromb Vasc Biol,2007,27(2):366-372.
[35]Dewey FE,Gusarova V,Dunbar RL,et al. Genetic and pharmacologic inactivation of
ANGPTL3 and cardiovascular disease[J]. N Engl J Med,2017,377(3):211-221.
[36]Stitziel NO,Khera AV,Wang X,et al. ANGPTL3 deficiency and protection against coronary artery disease[J]. J Am Coll Cardiol,2017,69(16):2054-2063.
[37]Graham MJ,Lee RG,Brandt TA,et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides[J]. N Engl J Med,2017,377(3):222-232.
相似文献/References:
[1]胥雪莲,何川.前蛋白转化酶枯草溶菌素9与动脉粥样硬化[J].心血管病学进展,2016,(1):50.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.013]
XU Xuelian,HE Chuan.Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(4):50.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.013]
[2]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(4):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[3]孟凡华 付真彦.一种新型的治疗血脂异常的干扰RNA药物Inclisiran[J].心血管病学进展,2021,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.018]
MENG Fanhua,FU Zhenyan.Inclisiran, A New Small Interfering RNA Drug for the Treatment of Dyslipidemia[J].Advances in Cardiovascular Diseases,2021,(4):167.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.018]
[4]刘力黎 陈诚 张丽敏.血脂水平与心房颤动相关性研究进展[J].心血管病学进展,2021,(6):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
LIU Lili,CHEN Cheng,ZHANG Limin.Serum Lipid Level and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(4):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
[5]袁荣辉 白春林.贝派地酸降脂疗效及安全性的研究进展[J].心血管病学进展,2021,(9):809.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
(.Shanxi Medical University,Taiyuan 0000,Shanxi,et al.YUAN Ronghui1,BAI Chunlin2[J].Advances in Cardiovascular Diseases,2021,(4):809.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[6]肖明瑛 苏冠华.PCSK9抑制剂多效性研究进展[J].心血管病学进展,2022,(2):124.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.008]
XIAO MingyingSU Guanhua.Pleiotropic Effects of PCSK9 Inhibitors[J].Advances in Cardiovascular Diseases,2022,(4):124.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.008]
[7]王兰 叶玉兰 宁明安 张迪 尚粉青.血清PCSK9水平与PCI后冠状动脉病变再进展的关系研究[J].心血管病学进展,2022,(7):667.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
WANG Lan,YE Yulan,NING Mingan,et al.Correlation Analysis Between Serum PCSK9 Level and Coronary Artery Pathological ?Progression After PCI[J].Advances in Cardiovascular Diseases,2022,(4):667.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[8]许晓宇 唐炯 郑甲林.PCSK9对血管内皮功能影响的研究进展[J].心血管病学进展,2023,(6):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]
XU Xiaoyu,TANG Jiong,ZHENG Jialin.Research Progress on the Effects of PCSK9 on Vascular Endothelial Function[J].Advances in Cardiovascular Diseases,2023,(4):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]
[9]黄橙 李波 李志勇 陈紫君.过低LDL-C在动脉粥样硬化性心血管疾病中潜在风险循证学证据[J].心血管病学进展,2023,(11):1041.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.019]
Huang Cheng,Li Bo,Li Zhiyong,et al.The Evidence of the Potential Risk of Excessively Low Levels of LDL-C in ASCVD[J].Advances in Cardiovascular Diseases,2023,(4):1041.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.019]
[10]李开炜 彭汶婷 祝烨.降脂药物与认知功能下降的研究进展[J].心血管病学进展,2024,(3):220.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.007]
LI Kaiwei,PENG Wenting,ZHU Ye.Lipid-Lowering Drugs and Cognitive Function Decline[J].Advances in Cardiovascular Diseases,2024,(4):220.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.007]
[11]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(4):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[12]许海南 龙明智.新型降脂药物干扰小RNA Inclisiran最新研究进展[J].心血管病学进展,2021,(7):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
XU Hainan,LONG Mingzhi.Small Interfering RNA Inclisiran[J].Advances in Cardiovascular Diseases,2021,(4):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
[13]刘杨 陈明.冠心病的治疗新方向——PCSK9抑制剂[J].心血管病学进展,2021,(9):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
New Direction of Coronary Heart Disease TreatmentPCSK9 Inhibitors.E-mailchenmingcq77@163.com[J].Advances in Cardiovascular Diseases,2021,(4):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]